Profit

Drug Price Cap to Impact Glaxo, Sanofi, Novartis most: Prabhudas Lilladher

PUBLISHED ON: July 15, 2014 | Duration: 10 min, 28 sec

  
loading..
Surjit Pal, pharma analyst at Prabhudas Lilladher says the government's move to cap prices of essential drugs is justified, but it will impact MNC pharma companies more as most domestic drugmakers have already de-risked their overall portfolio by venturing into export market.
ALSO WATCH
Regulatory Environment Unfavourable For Pharma Companies: Surjit Pal

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com